Integrative Analysis Identified MCT4 as an Independent Prognostic Factor for Bladder Cancer.
bladder cancer
immunohistochemistry
monocarboxylate transporter 4
single-cell RNA sequencing
solute carrier family 16 member 3
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
04
05
2021
accepted:
02
08
2021
entrez:
13
9
2021
pubmed:
14
9
2021
medline:
14
9
2021
Statut:
epublish
Résumé
Bladder cancer is the 10th most common cancer and most common urothelial malignancy worldwide. Prognostic biomarkers for bladder cancer patients are required for individualized treatment. Monocarboxylate transporter 4 (MCT4), encoded by The published single-cell RNA sequencing data of 49,869 bladder cancer cells and 15,827 normal bladder mucosa cells and The Cancer Genome Atlas (TCGA) bladder cancer cohort data were used to explore the mRNA expression of SLC16A3 in bladder cancer. Eighty-nine consecutive bladder cancer patients who had undergone radical cystectomy were enrolled as a validation cohort. The expression of MCT4 proteins in bladder cancer specimens was detected using immunohistochemistry staining. The Kaplan-Meier survival analysis and Cox regression were performed to analyze the association between MCT4 protein expression and OS in bladder cancer patients. SLC16A3 mRNA was upregulated in bladder cancer cells. The upregulated genes in SLC16A3-positive epithelial cells were enriched in the glycolysis process pathway and monocarboxylic acid metabolic process pathway. Patients with high SLC16A3 mRNA expression showed significantly poor OS (p = 0.016). High MCT4 protein expression was also found to be an independent predictor for poor OS in bladder cancer patients (HR: 2.462; 95% CI: 1.202~5.042, p = 0.014). A nomogram was built based on the results of the multivariate Cox analysis. Bladder cancer with high SLC16A3 mRNA expression has a poor OS. High MCT4 protein expression is an independent prognostic factor for bladder cancer patients who had undergone radical cystectomy.
Sections du résumé
BACKGROUND
BACKGROUND
Bladder cancer is the 10th most common cancer and most common urothelial malignancy worldwide. Prognostic biomarkers for bladder cancer patients are required for individualized treatment. Monocarboxylate transporter 4 (MCT4), encoded by
METHODS
METHODS
The published single-cell RNA sequencing data of 49,869 bladder cancer cells and 15,827 normal bladder mucosa cells and The Cancer Genome Atlas (TCGA) bladder cancer cohort data were used to explore the mRNA expression of SLC16A3 in bladder cancer. Eighty-nine consecutive bladder cancer patients who had undergone radical cystectomy were enrolled as a validation cohort. The expression of MCT4 proteins in bladder cancer specimens was detected using immunohistochemistry staining. The Kaplan-Meier survival analysis and Cox regression were performed to analyze the association between MCT4 protein expression and OS in bladder cancer patients.
RESULTS
RESULTS
SLC16A3 mRNA was upregulated in bladder cancer cells. The upregulated genes in SLC16A3-positive epithelial cells were enriched in the glycolysis process pathway and monocarboxylic acid metabolic process pathway. Patients with high SLC16A3 mRNA expression showed significantly poor OS (p = 0.016). High MCT4 protein expression was also found to be an independent predictor for poor OS in bladder cancer patients (HR: 2.462; 95% CI: 1.202~5.042, p = 0.014). A nomogram was built based on the results of the multivariate Cox analysis.
CONCLUSION
CONCLUSIONS
Bladder cancer with high SLC16A3 mRNA expression has a poor OS. High MCT4 protein expression is an independent prognostic factor for bladder cancer patients who had undergone radical cystectomy.
Identifiants
pubmed: 34513685
doi: 10.3389/fonc.2021.704857
pmc: PMC8426349
doi:
Types de publication
Journal Article
Langues
eng
Pagination
704857Informations de copyright
Copyright © 2021 Zhao, Zhao, Yan, Xia, Wang, Zheng, Wang and Zhang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Commun. 2020 Oct 8;11(1):5077
pubmed: 33033240
Mol Carcinog. 2015 Nov;54(11):1451-66
pubmed: 25263481
Genome Med. 2020 May 27;12(1):47
pubmed: 32460812
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
World J Urol. 2019 Mar;37(3):507-514
pubmed: 29992381
BJU Int. 2020 Nov;126(5):610-619
pubmed: 32783347
Clin Cancer Res. 2016 Jun 1;22(11):2721-33
pubmed: 26755530
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Science. 1956 Aug 10;124(3215):270-2
pubmed: 13351640
Eur Urol Oncol. 2018 Oct;1(5):403-410
pubmed: 31158079
Eur Urol. 2020 Jan;77(1):101-109
pubmed: 31699526
Oncol Rep. 2016 Aug;36(2):945-51
pubmed: 27373212
Urology. 2014 Jul;84(1):245.e9-15
pubmed: 24857275
World J Urol. 2019 Sep;37(9):1741-1749
pubmed: 30283995
Nat Methods. 2015 Feb;12(2):115-21
pubmed: 25633503
Urol Int. 2019;103(3):291-296
pubmed: 31461728
BJU Int. 2016 Apr;117(4):604-10
pubmed: 25851271
Genes Dev. 2009 Mar 1;23(5):537-48
pubmed: 19270154
Oncol Res Treat. 2015;38(3):117-22
pubmed: 25792083
Clin Genitourin Cancer. 2017 Aug;15(4):e661-e666
pubmed: 28188046
Mol Cancer Ther. 2018 Dec;17(12):2746-2755
pubmed: 30262589
J Magn Reson Imaging. 2020 Sep 17;:
pubmed: 32939939
Int J Cancer. 2012 Apr 1;130(7):1511-20
pubmed: 21484790
Pflugers Arch. 2004 Feb;447(5):619-28
pubmed: 12739169
Mol Cancer. 2013 Dec 03;12:152
pubmed: 24298908
J Natl Compr Canc Netw. 2020 Mar;18(3):329-354
pubmed: 32135513
Cancers (Basel). 2020 Oct 15;12(10):
pubmed: 33076505
Oncologist. 2019 May;24(5):612-616
pubmed: 30944184
Science. 2009 May 22;324(5930):1029-33
pubmed: 19460998
BMC Cancer. 2019 Sep 9;19(1):897
pubmed: 31500577
Clin Cancer Res. 2013 Sep 15;19(18):5170-81
pubmed: 23881922
Urol Oncol. 2020 May;38(5):459-464
pubmed: 32173242
Nat Biotechnol. 2018 Jun;36(5):411-420
pubmed: 29608179
Nat Biotechnol. 2018 Dec 03;:
pubmed: 30531897
Transl Androl Urol. 2021 Feb;10(2):626-635
pubmed: 33718065
J Pers Med. 2021 Mar 23;11(3):
pubmed: 33806972
Oncotarget. 2015 Nov 17;6(36):39196-210
pubmed: 26474279
Eur Urol Oncol. 2020 Jun;3(3):306-315
pubmed: 32199915
Compr Physiol. 2013 Oct;3(4):1611-43
pubmed: 24265240
Cell. 2019 Jun 13;177(7):1888-1902.e21
pubmed: 31178118
J Cancer Res Clin Oncol. 2017 Oct;143(10):1971-1976
pubmed: 28555356
Med Oncol. 2014 Sep;31(9):21
pubmed: 25085780
Int J Mol Sci. 2018 Aug 24;19(9):
pubmed: 30149597
Cell Cycle. 2016;15(3):368-80
pubmed: 26636903